GRI

AIFA Board of Directors approves the reclassification of glifozines in class A of reimbursed products that can be purchased in pharmacies

News Healthcare & Pharma Law & Policy Updates
Date: 30th Jun, 2025 Source: Italian Medicines Agency (AIFA) Country: Italy Original Source

Brief

On 30/06/2025, the Italian Medicines Agency (AIFA) issued an update regarding AIFA Board of Directors approves the reclassification of glifozines in class A of reimbursed products that can be purchased in pharmacies. This change aims to simplify and streamline access to these medications, reducing costs by eliminating the need for specialist visits for prescription renewal.

This content is restricted.

Highlights content goes here...

This content is restricted.

Italian Medicines Agency (AIFA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
32 million euros for patent calls+, drawings+ and brands+ from 2025
Date: 2nd Sep, 2025 Source: Italian Patent and Trademark Office Country: Italy
News Intellectual property Law & Policy Updates
CFTC Issues Policy Statement on Referrals for Potential Criminal Enforcement
Date: 5th Sep, 2025 Source: Commodity Futures Trading Commission (CFTC) Country: USA
News Corporate Finance & M&A Law & Policy Updates
US Department of Labor unveils proposals to put American workers, businesses first in release of semiannual regulatory agenda
Date: 4th Sep, 2025 Source: US Department of Labor Country: USA
News Employment & labor Law & Policy Updates

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales